RA patients on upadacitinib and methotrexate showed robust antibody and T-cell responses to the recombinant zoster vaccine over 60 weeks. The vaccine maintained a satisfactory humoral response in 71.4 ...
Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity. Phase 1 study of DK210 (EGFR), a tumor-targeted IL2 x IL10 dual ...
Our NAV-005 antagonist binds the immunosuppressive HIO-1 factor and blocks its ability to suppress mAb, TCE and ADC ...
A research team from POSTECH and ImmunoBiome in Korea, led by Professor Sin-Hyeog Im, has uncovered a new mechanism showing ...
Antigen presenting cells capture tumour antigen within the tumour microenvironment and migrate to tumour-draining lymph nodes where they prime tumour-reactive T cells. Tumour-reactive T cells then ...
Durable complete responses with CAR-NK + Rituximab in patients who failed current standards of care in Waldenstrom’s Non-Hodgkins lymphoma (NHL). Long-term evaluable patients demonstrate ongoing ...
A man with long-standing type 1 diabetes underwent transplant with UP421 gene-edited islet cells designed to avoid rejection. Even without immunosuppression, the patient remained free of an immune ...
First Phase 2 chemotherapy-free, lymphodepletion-free, off-the-shelf CAR-NK cell therapy plus ANKTIVA® and rituximab regimen ...
A groundbreaking phase 2 trial explores a novel, chemotherapy-free immunotherapy for relapsed indolent B-cell lymphomas, aiming to enhance patient outcomes.
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced updated efficacy and safety results from the ongoing QUILT-106 clinical study (NCT06334991) evaluating an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results